Skip to main content
. Author manuscript; available in PMC: 2018 Oct 10.
Published in final edited form as: J Control Release. 2017 Mar 21;263:200–210. doi: 10.1016/j.jconrel.2017.03.033

Figure 5.

Figure 5

Schematic illustration of a combined anti-tumor approach that included nanovaccine, cytokine, checkpoint inhibitor and a tumor-antigen antibody. Reprinted with permission from Ref.123.